Send to

Choose Destination
Int J Clin Exp Pathol. 2015 Sep 1;8(9):11393-9. eCollection 2015.

Expression of pyruvate kinase M2 in human colorectal cancer and its prognostic value.

Author information

Department of Gastrointestinal Surgery, Jiading Hospital of Traditional Chinese Medicine Shanghai 201800, P. R. China.


Reprogrammed metabolism is a hallmark of cancer cells. Pyruvate kinase isozyme type M2 (PKM2), which is frequently up-regulated in multiple human malignancies, has been demonstrated to play a critical function in glucose metabolism, gene transcription and tumorigenesis. However, limited knowledge is known about the expression pattern and prognostic value of PKM2 in colorectal cancer (CRC). In this study, we first observed that the mRNA level of PKM2 is commonly up-regulated in CRC tissues compared with their normal counterparts as demonstrated by data derived from Oncomine database. Similar results were also found in 32 paired CRC tumor and non-tumor specimens in our cohort and 4 CRC cell lines. Furthermore, by a large scale of immunohistochemical analysis in a tissue microarray containing 345 cases of CRC specimens, we demonstrated that the protein expression of PKM2 expression is up-regulated in 79.4% (274/345) samples detected and elevated PKM2 expression is closely correlated with enhanced TNM stage and higher serum CEA level. Meanwhile, Kaplan-Meier survival analysis showed that CRC patients with a higher PKM2 expression have a poorer clinical outcome than those with a lower PKM2 expression. Multivariate Cox regression analysis revealed that PKM2 and TNM stage are two independent prognostic factors for overall survival rate of CRC patients. Taken together, our studies reveal the prognostic value of PKM2 in CRC and support that PKM2 may act as a molecular target for CRC treatment.


PKM2; colorectal cancer; prognosis; therapy

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center